截至2026年1月7日收盘，化工ETF天弘(159133)换手5.12%，成交3602.52万元。跟踪的中证细分化工产业主题指数(000813)下跌 0.54%。成分股方面涨跌互现，彤程新材(603650)领涨10.00%，蓝晓科技(300487)上涨6.02%，浙江龙盛(600352)上涨3.41%。 值得一提的是，化工ETF天弘(159133)全天获资金净申购1500万份。 | | 化工ETF天弘 159133 | ਕੋ | | --- | --- | --- | | | | * Q F | | 实时申购赎回信息 | 申购 | 赎回 | | 笔数 | 3 | 7 | | 金额 | 0 | 0 | | 份额 | 1850万 | 350万 | 拉长时间看，截至1月7日，化工ETF天弘(159133)最新规模达7.18亿元，最新份额达6.22亿份，均创成立以来新高。 从资金净流入方面来看，化工ETF天弘(159133)近6天获得连续资金净流入，合计"吸金"1.04亿元。 【产品亮点】 从成长逻辑看，新能源材料、高性能塑料、生物基化工等新兴领域具备长期成长空间。龙头企业通过加大研发投入、完善产业 链布局，有望在新 ...

截至2026年1月5日收盘，中证A500ETF天弘(159360)换手2.95%，成交5555.01万元。跟踪的中证A500指数(000510)强势上涨 2.14%，成分股乐普医疗(300003)上涨19.99%，蓝色光标(300058)上涨19.97%，汤姆猫(300459)上涨16.34%，中微公司(688012)， 罗博特科(300757)等个股跟涨。 拉长时间看，截至1月5日，中证A500ETF天弘(159360)近8个交易日合计"吸金"8651.13万元。 【产品亮点】 中证A500ETF天弘(159360)助力布局中国核心资产，该ETF跟踪中证A500指数，采取行业均衡配置与龙头优选双策略，融合价 值与成长属性，相比沪深300，超配电力设备新能源、电子、医药生物等新质生产力行业，具备天然的哑铃投资属性。 【相关产品】 中证A500ETF天弘(159360)，对应场外场外联接(A：022428；C：022429；Y：022966)。 【热点事件】 1、资金政策共振发力，沪指时隔34个交易日重返4000点 2026年1月5日，A股新年首个交易日迎来"开门红"，上证指数高开高走，时隔34个交易日再度站上 ...

每经编辑：叶峰 A股今日早盘高开高走，创新药、脑机接口等概念股盘中爆发，昭衍新药、百济神州-U涨超10%，益方 生物-U、美迪西涨约8%。 受盘面影响，创新药ETF天弘（517380）跟踪的恒生沪深港创新药精选50指数盘中大涨超4.8%，涨幅超 过港股通创新药指数。此外，生物医药ETF（159859）跟踪的国证生物医药指数涨超3%，该产品规模 超33亿元，自去年9月以来累计净流入资金超6亿元。 消息面上，国家药监局日前组织制订《优先审批高端医疗器械目录（2025版）》，将医用电子加速器、 植入式脑机接口医疗器械、内窥镜手术控制系统等纳入其中。另外，马斯克近日在社交媒体上表示，其 脑机接口公司"神经连接"将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几乎 完全自动化的外科手术流程"。 有券商表示，将植入式脑机接口医疗器械等8类高端产品纳入优先审批范围，进一步凸显政策对相关技 术发展的支持力度。脑机接口赛道具备多元化的应用场景与丰富的研发路径，未来潜在市场空间广阔， 叠加产品注册与医保立项等政策支持，商业化进程有望加速。 从市场前景看，麦肯锡也给出了一份测算，认为全球脑机接口医疗应用的潜在 ...

Core Insights - The article highlights the performance of the Tianhong Innovation Drug ETF (517380), which has seen a trading volume of 14.27 million yuan and a nearly 3% increase in the tracked Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID) [1] - The article discusses a new three-year enhancement plan for the biopharmaceutical industry in Xi'an, indicating a new policy support cycle for the innovative drug sector [1][2] Product Highlights - The Tianhong Innovation Drug ETF (517380) spans the Shanghai, Hong Kong, and Shenzhen markets, selecting 50 leading innovative drug companies, with 40% from Hong Kong and 60% from A-shares, covering core areas such as biopharmaceuticals and chemical pharmaceuticals [1] - Related products include the Tianhong Innovation Drug ETF and its corresponding off-market connection funds (Class A: 014564, Class C: 014565) [1] Industry Developments - Xi'an's government has released an implementation plan for 2025-2027, aiming to achieve breakthroughs in key drug development technologies in areas such as stem cell drugs, peptide drugs, liver-targeted innovative drugs, and anesthetics [2] - By 2027, Xi'an aims to have one clinically approved drug and one production-approved drug in the innovative drug R&D field, along with 40 Class III and 400 Class II medical devices approved [2] - The innovative drug sector is entering a new policy support cycle, with various cities like Beijing and Shanghai implementing supportive policies for the pharmaceutical and health industry [2] Institutional Perspectives - Zhongtai Securities views innovative drugs as the most important theme in the pharmaceutical sector, noting that the recent 2-3 month market adjustment has brought stock prices, market expectations, and capital allocation back to relatively reasonable and low levels, highlighting investment safety margins and return value [2]

重磅发声！适度拓宽券商资本空间与杠杆上限 截至2025年12月8日午间收盘，证券ETF(159841)换手5.49%，成交6.04亿元。跟踪指数中证全指证券公司指 数(399975)早盘涨超3%，成分股兴业证券(601377)上涨10.00%，东北证券(000686)上涨5.20%，华泰证券 (601688)上涨4.27%，国泰海通(601211)，华安证券(600909)等个股跟涨。 截至12月5日，证券ETF(159841)近2周规模增长1.92亿元，近1月份额增长5.14亿份，实现显著增长。证券 ETF(159841)最新份额达99.99亿份。 资金流入方面，证券ETF(159841)近20个交易日合计"吸金"5.62亿元。 【产品亮点】 如果股市的 "财富效应"逐步加强，"牛市旗手"证券产业投资机遇不容忽视，深市规模流动性同类持续领先 的证券ETF(159841)助力把握机遇。 【相关产品】 证券ETF(159841)，对应场外联接基金（A：008590，C：008591）。 【热点事件】 159360 中证A500ETF天弘 A股风向标 12月6日，在中国证券业协会第八次会员大会上，证监会主席围绕《 ...

Core Insights - The securities ETF (159841) has seen significant trading activity, with a transaction volume of 234 million yuan and a recent increase in the underlying index by 0.56% [1] - The ETF has experienced a notable growth in scale, with an increase of 33.51 million yuan over the past week, reaching a new high of 9.678 billion shares [1][2] - The recent merger of China International Capital Corporation (CICC) with Dongxing Securities and Xinda Securities is expected to reshape the competitive landscape of the securities industry [4][5] Fund Performance - The securities ETF (159841) has attracted a total net inflow of 488 million yuan over the past week, with a peak single-day inflow of 173 million yuan [1][2] - The ETF's current scale stands at 10.702 billion yuan, making it the largest and most liquid securities ETF in the Shenzhen market [2] Merger Details - CICC is leading the merger with Dongxing Securities and Xinda Securities, utilizing a share exchange method to absorb both firms [4] - As of September 2025, CICC's net assets were 115.5 billion yuan, while Dongxing and Xinda had net assets of 29.6 billion yuan and 26.4 billion yuan, respectively, resulting in a combined net asset exceeding 170 billion yuan post-merger [4][5] Strategic Implications - The merger is expected to enhance CICC's capabilities in debt restructuring and risk resolution, leveraging the expertise of Dongxing and Xinda in managing non-performing assets [5] - The combined entity will not only maintain its leadership in traditional investment banking but also strengthen its retail brokerage and regional market presence, creating a more balanced business model [5] - The merger is anticipated to generate "scale effects + business synergy," leading to improved revenue structure and profitability [5][6]

Core Viewpoint - The Shanghai Composite Index has reached the 4000-point mark for the first time in 10 years, indicating significant changes in the A-share market as it approaches the end of 2025 and the commencement of the next five-year plan in China [1] Group 1: Major Changes in the Market - Change One: Slow Bull Market - The Shanghai Composite Index rose from 2748 points on September 24, 2022, to surpass 4000 points on October 28, 2023, taking 400 days with an annualized volatility of 15.28%. In comparison, previous surges in 2007 and 2015 took only 89 and 127 days, respectively, with higher volatilities of 27.94% and 23.01% [1] - Change Two: Shift in A-share Pricing Power - By Q3 2024, the scale of passive equity funds, particularly stock ETFs, has surpassed that of actively managed equity funds for the first time, with the current ETF market reaching 5 trillion yuan, indicating a significant shift in pricing power within the A-share market [4] - Change Three: Leading Themes in the Current Market - The current bull market is primarily driven by sectors such as communication, electronics, and power equipment, reflecting a broader trend towards technological self-sufficiency and the global AI wave, alongside the narrative of revaluation of Chinese assets [5] Group 2: Fund Flows and Investment Trends - Significant Capital Inflows - Since September 24, 2022, the ETF market has seen a net inflow of 1.17 trillion yuan, with major inflows directed towards core A-share assets, technology innovation, and cyclical sectors [11][12] - Performance of Key ETFs - The Double Innovation Leader ETF tracking the Sci-Tech Innovation 50 Index has risen by 57.63% this year, while the Tianhong Growth ETF tracking the ChiNext Index has increased by 45.78% [8] - Year-End Capital Rotation - Following six months of continuous growth, A-shares have seen a rotation of capital, with significant inflows into ETFs tracking sectors like technology, securities, and consumer goods, particularly in the context of the upcoming "15th Five-Year Plan" [14][18]

Group 1 - The A-share market saw a collective low opening on October 31, with the innovative drug concept experiencing a volatile rebound [1] - The Tianhong Innovative Drug ETF (517380) rose by 2.15%, with a trading volume exceeding 10 million yuan, and recorded a net inflow of over 12 million yuan on October 30 [1] - The Biopharmaceutical ETF (159859) increased by 0.72%, with a trading volume exceeding 42 million yuan, and saw a net subscription of over 50 million units during the session [1] Group 2 - The Biopharmaceutical ETF closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the biopharmaceutical industry based on market capitalization and liquidity [2] - A notification from seven departments, including the National Health Commission, announced that the HPV vaccine will be included in the national immunization program starting November 10, 2025, for girls born after November 10, 2011 [2] - The 2025 National Medical Insurance negotiations began on October 30, introducing a "commercial insurance innovative drug directory" mechanism for the first time [2] Group 3 - Huafu Securities expressed optimism about the innovative drug sector, predicting a significant transformation over the next 5-10 years driven by international expansion, continuous data catalysts, and new product sales [2] - Industrial trends in the innovative drug sector remain positive, with a focus on "innovation + internationalization" [3] - The innovative drug sector's resilience is expected to improve further after short-term adjustments, with a focus on the improving fundamentals of the innovative drug industry chain [3]

Group 1 - The recent recovery of the innovative drug concept has been observed, with related ETFs showing positive performance, particularly the Tianhong Innovative Drug ETF (517380) which saw a peak increase of nearly 2% and is currently up 1.14% [1] - The Biopharmaceutical ETF (159859) has also shown a rise of 1.19%, with a trading volume close to 70 million yuan, leading among similar products [2] - Heng Rui Medicine has received approval for multiple injectable drug clinical trials, indicating a positive development in the biopharmaceutical sector [2] Group 2 - Investment firms like CMB International and Founder Securities express optimism about the innovative drug sector, suggesting that recent market corrections may present buying opportunities [2][3] - The Tianhong Innovative Drug ETF (517380) is noted as the largest in the market, covering a wide range of innovative drugs across the Hong Kong and mainland markets [3] - The Biopharmaceutical ETF (159859) closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the sector based on market capitalization and liquidity [3]

Group 1 - The ETF market opened with mixed performance on September 29, with notable gains in specific sectors [1] - The Southern Science and Technology Growth ETF (589700) increased by 9.61%, indicating strong investor interest in this sector [1] - The Energy Storage Battery ETF from GF (159305) rose by 2.24%, reflecting positive sentiment in the energy storage market [1] Group 2 - The Information Technology ETF (562560) saw a gain of 2.09%, suggesting a stable outlook for technology investments [1] - Conversely, the Communication Equipment ETF (159583) declined by 1.98%, indicating potential challenges in this sector [1] - The ChiNext Artificial Intelligence ETF from Huaan (159279) fell by 1.7%, and the Innovative Drug ETF from Tianhong (517380) decreased by 1.65%, highlighting some volatility in these emerging sectors [1]